Roivant Sciences (ROIV) stock
NASDAQ
As of the Nov 13, 2026 close (U.S. Eastern)
Events and reference metrics · 1
- Market cap
- $28.7B
- As of Nov 13, 2026
- P/E
- -95.56x
- Latest fiscal year
- P/B
- 7.13x
- Latest reported equity
- P/S
- Not available
- Latest fiscal year
- ROE
- -7.5%
- Latest fiscal year
- Dividend yield
- Not available
- Latest fiscal-year dividends
Multiples use the price as of Nov 13, 2026 and may differ from the current price.
- Market cap
- $28.7B
- As of Nov 13, 2026
- P/E
- -95.56x
- Latest fiscal year
- P/B
- 7.13x
- Latest reported equity
- P/S
- Not available
- Latest fiscal year
- ROE
- -7.5%
- Latest fiscal year
- Dividend yield
- Not available
- Latest fiscal-year dividends
Multiples use the price as of Nov 13, 2026 and may differ from the current price.
Compares the share price with the company's earnings, net assets and sales. Check trading status and financial notes separately.
Price date for the multiples · Nov 13, 2026 · Financial period · Latest fiscal year
Latest fiscal-year financials · Computed in-house by ChickenStock
P/E
-95.56x
Net loss — not comparable
P/B
7.13x
P/S
—
Earnings and dividend metrics▾
Earnings
EPS
-$0.41
Earnings per share
BPS
$5.54
Book value per share
ROE
-7.5%
Return on equity
- EPS — what one share earned over the last four quarters. The company is currently loss-making, at $0.41 per share.
- BPS — net assets divided by the number of shares. Each share is backed by $5.54 of net assets.
- ROE — shareholder equity shrank by 7.5% over a year.
ⓘ What are these valuation metrics?▾
P/E = share price ÷ earnings per share (EPS)
P/B = share price ÷ book value per share (BPS)
P/S = share price ÷ sales per share
P/E shows how many times annual earnings per share the price is; not all earnings are paid to shareholders. P/B compares the price with net assets, and P/S with sales.
Higher or lower is not good or bad by itself. Typical levels differ by industry; read P/B alongside ROE and P/S alongside margins.
ChickenStock computes these from SEC financial filings: net income and revenue are summed over the latest four quarters, and equity is the latest reported balance.
A negative P/E means a net loss. Reference information only, not a recommendation to buy or sell.
Latest earnings
SEC filingsJul–Sep 2026(FY2026 Q2)
Revenue increased 1,650.0% from the same period a year earlier.
Key reported figures come first. Select one to see the same quarter across three years.
Revenue · same quarter, three years
Year-ago quarter $2M+1,650.0%
$8M
Jul–Sep '24
$2M
Jul–Sep '25
$35M
Jul–Sep '26
The next earnings date has not been confirmed yet.
ⓘ Notes on these figures▾
- Results for Jul–Sep 2026 are from the 10-Q submitted to SEC EDGAR on Nov 9, 2026.
- Earnings per share decreased from a year earlier. The year-ago value was zero or negative, so no percentage change is shown.
- Revenue increased 1,650.0% from the same quarter a year earlier.
- Operating income increased from a year earlier. The year-ago value was zero or negative, so no percentage change is shown.
- Net income decreased from a year earlier. The year-ago value was zero or negative, so no percentage change is shown.
Filed Nov 9, 2026 · 10-Q · SEC EDGAR
Reported results are from SEC EDGAR filings. Reference information only, not investment advice.
Insider transactions
Recent Form 4 filings grouped by person, date and transaction type.
- Torti FrankPresident and Vant Chair · Nov 12, 2026Other392,043 shares · $15.9MAvg. price $40.4827
Show 2 price lots
- 329,550 shares × $40.36$13.3M
- 62,493 shares × $41.13$2.6M
- Sukhatme MayukhPresident & CIO · Nov 12, 2026Other53,205 shares · $2.2MAvg. price $40.4828
Show 2 price lots
- 44,723 shares × $40.36$1.8M
- 8,482 shares × $41.13$349K
- Gline MatthewCEO · Nov 12, 2026Other48,988 shares · $2.0MAvg. price $40.4827
Show 2 price lots
- 41,179 shares × $40.36$1.7M
- 7,809 shares × $41.13$321K
- Torti FrankPresident and Vant Chair · Nov 12, 2026Shares withheld for taxes12,800 shares · $536KAvg. price $41.8512,306,950 shares held after
- Sukhatme MayukhPresident & CIO · Nov 12, 2026Shares withheld for taxes1,737 shares · $73KAvg. price $41.8518,396,703 shares held after
- Gline MatthewCEO · Nov 12, 2026Shares withheld for taxes1,600 shares · $67KAvg. price $41.8516,391,229 shares held after
- Pulik RichardCFO · Nov 11, 2026Open-market sale175,000 shares · $7.3MAvg. price $41.8473
Show 3 price lots
- 82,170 shares × $42.03$3.5M
- 47,635 shares × $41.89$2.0M
- 45,195 shares × $41.47$1.9M
- Torti FrankPresident and Vant Chair · Nov 11, 2026Other392,048 shares · $16.4MAvg. price $41.7766
Show 2 price lots
- 240,755 shares × $41.63$10.0M
- 151,293 shares × $42.01$6.4M
- Sukhatme MayukhPresident & CIO · Nov 11, 2026Other53,205 shares · $2.2MAvg. price $41.7767
Show 2 price lots
- 32,672 shares × $41.63$1.4M
- 20,533 shares × $42.01$863K
- Gline MatthewCEO · Nov 11, 2026Other48,988 shares · $2.0MAvg. price $41.7766
Show 2 price lots
- 30,083 shares × $41.63$1.3M
- 18,905 shares × $42.01$794K
- Pulik RichardCFO · Nov 11, 2026Option exercise127,365 shares · $490KAvg. price $3.85397,046 shares held after
- Venker EricPresident & Immunovant CEO · Nov 10, 2026Open-market sale187,943 shares · $7.6MAvg. price $40.5286
Show 2 price lots
- 158,194 shares × $40.44$6.4M
- 29,749 shares × $41$1.2M
- Pulik RichardCFO · Nov 10, 2026Open-market sale125,000 shares · $5.2MAvg. price $41.2269,681 shares held after
- Torti FrankPresident and Vant Chair · Nov 10, 2026Other392,052 shares · $16.0MAvg. price $40.8199
Show 2 price lots
- 218,369 shares × $41.13$9.0M
- 173,683 shares × $40.43$7.0M
- Sukhatme MayukhPresident & CIO · Nov 10, 2026Other59,034 shares · $2.4MAvg. price $40.8199
Show 2 price lots
- 32,882 shares × $41.13$1.4M
- 26,152 shares × $40.43$1.1M
- Gline MatthewCEO · Nov 10, 2026Other58,331 shares · $2.4MAvg. price $40.8199
Show 2 price lots
- 32,490 shares × $41.13$1.3M
- 25,841 shares × $40.43$1.0M
- Pulik RichardCFO · Nov 10, 2026Option exercise125,000 shares · $481KAvg. price $3.85394,681 shares held after
- Venker EricPresident & Immunovant CEO · Nov 3, 2026Open-market sale200,000 shares · $7.3MAvg. price $36.31999,154 shares held after
- Venker EricPresident & Immunovant CEO · Oct 28, 2026Open-market sale200,000 shares · $7.3MAvg. price $36.591,199,154 shares held after
- Epperly Melissa B,Director · Oct 23, 2026Shares withheld for taxes116 shares · $4KAvg. price $36.4915,351 shares held after
- MOMTAZEE JAMES CDirector · Oct 23, 2026Shares withheld for taxes77 shares · $3KAvg. price $36.49112,265 shares held after
- Epperly Melissa B,Director · Oct 23, 2026Grant or award513 shares · $0Avg. price $015,467 shares held after
- MOMTAZEE JAMES CDirector · Oct 23, 2026Grant or award383 shares · $0Avg. price $0112,342 shares held after
- Oren IlanDirector · Oct 23, 2026Grant or award810 shares · $0Avg. price $0124,490 shares held after
- Venker EricPresident & Immunovant CEO · Oct 20, 2026Open-market sale200,000 shares · $7.0MAvg. price $35.1133
Show 2 price lots
- 185,856 shares × $35.09$6.5M
- 14,144 shares × $35.42$501K
- Gline MatthewCEO · Oct 16, 2026Shares withheld for taxes34,638 shares · $1.2MAvg. price $33.5316,549,136 shares held after
- Sukhatme MayukhPresident & CIO · Oct 16, 2026Shares withheld for taxes19,976 shares · $670KAvg. price $33.5318,563,884 shares held after
Only transactions reported on SEC Form 4 are shown. A sale may follow a pre-arranged 10b5-1 plan, and items such as option exercises or shares withheld for taxes are not open-market trades.
Recent SEC filings
40 filingsFilings submitted to the U.S. Securities and Exchange Commission (EDGAR). Dates are SEC filing dates (U.S. Eastern). Form and item names are the official SEC titles. The Earnings and Risk tags come directly from form types and item codes; they are not written by AI. Insider ownership reports (Forms 3, 4 and 5) are excluded.
Company overview
Expand ▾
Roivant Sciences (ROIV) stock information
NASDAQ
Roivant Sciences (ROIV) is listed on NASDAQ. Its market capitalization is about $28.7B. On trailing-twelve-month earnings the P/E ratio is -95.56, and the P/B ratio is 7.13. Return on equity is -7.5%. These figures are computed in-house from official filings and are reference information only.
Roivant Sciences — frequently asked questions
- What is the P/E ratio of Roivant Sciences (ROIV)?
- On a trailing-twelve-month basis, ROIV trades at a P/E ratio of -95.56. It is calculated as market capitalization divided by net income attributable to controlling interests, using official filings. Reference information only.
- What is the market capitalization of Roivant Sciences?
- ROIV has a market capitalization of about $28.7B. The figure moves with the share price and is refreshed each trading day.
- Is this page investment advice?
- No. Every figure on this page is factual reference information compiled from public filings. It is not investment advice, not a price forecast and not a recommendation to buy or sell. Investment decisions rest with the user.
All metrics, scores, and content provided by ChickenStock are reference information derived from market data. They are not investment advice or a solicitation to trade. Investment decisions and their consequences rest with the user.